Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
Cost of Revenue
$446.00K
TTM · Period ending: · USD

LCTX Cost of Revenue
Latest reported$446.00Kperiod ending
Latest reported$446.00Kperiod ending
LCTX TTM Cost of Revenue ($600.00K → $446.00K)
TTM cost of revenue
High-resolution chart · PNG
LCTX cost of revenue history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Cost of Revenue (USD) |
|---|---|
| 446,000 | |
| 298,000 | |
| 146,000 | |
| 234,000 | |
| 267,000 | |
| 272,000 | |
| 509,000 | |
| 786,000 | |
| 917,000 | |
| 1,000,000 | |
| 846,000 | |
| 517,000 | |
| 583,000 | |
| 671,000 | |
| 728,000 | |
| 830,000 | |
| 1,580,000 | |
| 1,490,000 | |
| 1,426,000 | |
| 1,336,000 | |
| 453,000 | |
| 403,000 | |
| 385,000 | |
| 394,000 | |
| 406,000 | |
| 438,000 | |
| 412,000 | |
| 341,000 | |
| 262,000 | |
| 261,000 | |
| 302,000 | |
| 304,000 | |
| 321,000 | |
| 220,000 | |
| 168,000 | |
| 134,000 | |
| 140,000 | |
| 230,000 | |
| 398,000 | |
| 528,000 | |
| 902,000 | |
| 1,067,000 | |
| 1,106,167 | |
| 1,179,139 | |
| 978,040 | |
| 969,305 | |
| 837,052 | |
| 836,502 | |
| 812,279 | |
| 741,825 | |
| 792,660 | |
| 730,593 | |
| 693,649 | |
| 596,756 | |
| 434,275 | |
| 273,920 | |
| 122,702 | |
| 63,600 | |
| 43,332 | |
| 43,332 | |
| 24,816 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| -19,328 |